Karl Claxton
Professor of Economics

Profile

Biography

Karl Claxton is a Professor in the Department of Economics and Related Studies at the University of York. He is also a Senior Research Fellow in the Centre for Health Economics, University of York.

He was a  Harkness Fellow at the Harvard School of Public Health and from 1999 until 2007 he held an adjunct appointment at Harvard as an Assistant Professor of Health and Decision Sciences.

His research interests encompass the economic evaluation of health care technologies.

He has served as a member of the National Institute for Clinical Excellence Appraisal Committee since 1999. He has represented the committee at a number of appeals and was an expert witness for the Institute during the judicial review in 2007.  He is a member of the National Decision Support Unit and continues to contribute to the development of guidance for the appraisal of health technologies for NICE.  He is also co-editor of the Journal of Health Economics. 

Karl Claxton was born on 1st March 1967.  He received a PhD in Economics, a MSc in Health Economics and a BA in Economics all from the University of York

Research

Overview

  • His research interests encompass the economic evaluation of health care technologies

Research group(s)

Publications

Full publications list

2013

  • Claxton K, Griffin S, Koffijberg H, McKenna C. Expected health benefits of additional evidence: Principles, methods and applications. Centre for Health Economics, University of York; CHE Research Paper 83 (PDF , 1,068kb) 2013. PCORI Technical Appendix (PDF , 983kb)
  • Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M. Methods for the estimation of the NICE cost effectiveness threshold. Centre for Health Economics, University of York, CHE Research Paper 81 (PDF , 3,944kb)‌ 2013.
  • Edlin R, McCabe C, Round J, Wright J, Claxton K, Sculpher M, Cookson R. Understanding Harris’ understanding of CEA: is cost effective resource allocation undone? Journal of Health Services Research and Policy. 2013;18(1)(1):34-9.
  • Longworth L, Youn J, Bojke L, Palmer S, Griffin S, Spackman E, Claxton, K. When does NICE recommend the use of Health technologies within a programme of evidence development? : A systematic review of NICE guidance. Pharmacoeconomics  2013;31(2):137-49.
  • Soares MO, Dumville J, Ashby RL, Iglesias Urrutia CP, Bojke L, Adderley UJ, McGinnis E, Stubbs N, Torgerson D, Claxton K, Cullum N. Methods to assess cost effectiveness and value of further research when data are sparse: Negative-pressure wound therapy for severe pressure ulcers. Medical Decision Making 2013;33(3):415-36.‌

2012

  • Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, McKenna C, Soares M, Spackman DE, Youn J. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development. Health Technology Assessment 2012;16. Download from hta
  • Cookson R, Claxton K. The humble economist. Tony Culyer on health, health care and social decision making. Office of Health Economics, London and University of York, 2012. The humble economist 
  • Sculpher MJ, Claxton K. Real economics needs to reflect real decisions: (PDF , 177kb)‌‎ a response to Johnson. Pharmacoeconomics 2012;30:133-36.
  • Soares MO, Dumville J, Ashby R, Iglesias C, Bojke L, Adderley U, McGinnis E, Stubbs N, Torgerson D, Claxton K, Cullum N. Methods to assess cost effectiveness and value of further research when data are sparse: negative pressure wound therapy for severe pressure ulcers. Medical Decision Making 2012;doi:10.1177/0272989X12451058. Download from sagepub
  • Walker S, Griffin S, Claxton K, Palmer S, Sculpher M. Guest editorial, Appropriate perspectives for health care decisions. In: Curtis L, editor. Unit costs of health and social care 2012. Kent: PSSRU; 2012. p. 8-11. Download from pssru
  • Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions. Centre for Health Economics, University of York; CHE Research Paper 77 (PDF , 475kb)‌‎ 2012.
  • Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions. Value in Health 2012;15(3):570-579. More details from Value in Health

2011

Conference papers

  • Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, McKenna C, Soares M, Spackman E, Youn J. Uncertainty, evidence and irrecoverable costs: Informing approval, pricing and research decisions for health technologies. Centre for Health Economics, University of York; CHE Research Paper 69 (PDF , 1,860kb)‌‎ 2011.
  • Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer AJ. Discounting and decision making in the economic evaluation of health care technologies. Health Economics 2011;20:2-15. Download from Wiley interscience
  • Claxton K, Sculpher M, Carroll S. Value-based pricing for pharmaceuticals: its role, specification and prospects in a newly devolved NHS. Centre for Health Economics, University of York; CHE Research Paper 60 (PDF , 571kb)‌‎ , 2011.
  • Griffin S, Claxton K. Analysing uncertainty in cost-effectiveness for decision making. In: Glied S, Smith PC, editors. Oxford Handbook of Health Economics. Oxford: Oxford University Press; 2011.
  • Griffin S, Claxton K, Palmer S, Sculpher M. Dangerous omissions: the consequences of ignoring decision uncertainty. Health Economics 2011;20:212-24. Download from Wiley interScience
  • Jackson CH, Bojke L, Thompson SG, Claxton K, Sharples LD. A framework for addressing structural uncertainty in decision models. Medical Decision Making 2011;31(4):662-674.  Download from sagepub
  • McKenna C, Claxton K. Addressing adoption and research design decisions simultaneously: the role of value of sample information analysis. Medical Decision Making 2011;31:853-865.
  • Paulden M, Claxton K. Budget allocation and the revealed social rate of time preference for health. Health Economics 2011;doi:10.1002/hec.1730. Download from Wiley  
  • Soares MO, Bojke L, Dumville J, Iglesias C, Callum N, Claxton K. Methods to elicit experts' beliefs over uncertain quantities: application to a cost effectiveness transition model of negative pressure wound therapy for severe pressure ulceration. Statistics in Medicine 2011;30(19):2363-2380. Download from Wiley

2010

  • Bojke L, Claxton K, Bravo Vergel Y, Sculpher M, Palmer S, Abrams K. Eliciting distributions to populate decision analytic models. Value in Health 2010;13:557-64. Download from Wiley interscience 
  • Claxton K, Walker S, Palmer S, Sculpher M. Appropriate perspectives for health care decisions. Centre for Health Economics, University of York. CHE Research Paper 54 (PDF , 1,114kb)‌‎ , 2010.  
  • Griffin S, Claxton K, Welton N. Exploring the research decision space: the expected value of information for sequential research designs. Medical Decision Making 2010;30:155-62. Download from Sage journals
  • McCabe C, Chilcott J, Claxton K, Tappenden P, Cooper C, Roberts J, Cooper N, Abrams K. Continuing the multiple sclerosis risk sharing scheme is unjustified. British Medical Journal 2010;340 (C1786) Download from BMJ
  • McKenna C, Chalabi Z, Epstein D, Claxton K. Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions. Journal of Health Economics 2010; 29: 170–181. Download from Science Direct
  • McKenna C, Hawkins N, Claxton K, McDaid C, Suekarran S, Light K, Chester M, Cleland J, Woolacott N, Sculpher M. Cost-effectiveness of enhanced external counterpulsation (EECP) for the treatment of stable angina in the UK. International Journal of Technology Assessment in Health Care 2010;26(2):175-82. Download from Pubmed.gov
  • Sculpher M, Claxton K. Sins of omission and obfuscation: IQWiG’s guidelines on economic evaluation methods. Health Economics 2010;19(10):1132-36.
  • Walker S, Mason A, Claxton K, Cookson R, Fenwick E, Fleetcroft R, Sculpher M. Value for money and the quality and outcomes framework in primary care in the NHS. British Journal of General Practice 2010;60(574):213-20. Download from Ingentaconnect

2009

  • Bojke L, Claxton K, Sculpher M, Palmer S. Characterizing structural uncertainty in decision-analytic models: a review and application of methods. Value in Health. 2009;12:739-49.
  • Claxton K. Innovation Review - The value of innovation. Presentation at Kennedy Workshop on NICE's approach to valuing innovation,  London, May 19th 2009. The Value of Innovation (PDF , 143kb)‌‎
  • Conti S, Claxton K. Dimensions of design space: a decision theoretic approach to optimal research portfolio design. Medical Decision Making 2009;29:643-60. Download from Sage Journals online
  • Hoomans T, Fenwick E, Palmer S, Claxton K. Value of information and value of implementation: application of a framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer. Value in Health. 2009;12:315-24. Download from Wiley Interscience
  • McKenna C, McDaid C, Suekarran S, Hawkins N, Claxton K, Light K, Chester M, Cleland J, Woolacott N, Sculpher M. Enhanced external counterpulsation (EECP) for the treatment of stable angina and heart failure: A systematic review and economic analysis. Health Technology Assessment. 2009;13(24):1-112. Download from HTA.ac.uk
  • Paulden M, Claxton K. Budget allocation and the revealed social rate of time preference for health. Centre for Health Economics, University of York; CHE Research Paper 53 (PDF , 314kb)‌‎ , 2009.
  • Weatherly H, Drummond M, Claxton K, Cookson R, Ferguson B, Godfrey C, Sculpher M, et al. Methods for assessing the cost-effectiveness of public health interventions: key challenges and recommendations. Health Policy 209;93:85-92. Download  from elsevierhealth

2008

  • Bojke L, Claxton K, Sculpher M, Palmer S, Philips Z. The cost-effectiveness and value of information associated with repeat screening for age related macular degeneration. Medical Decision Making. 2008;28:33-43. Download from Sage Journals Online
  • Chalabi Z, Epstein D, McKenna C, Claxton K. Uncertainty and value of information when allocating resources within and between healthcare programmes. European Journal of Operational Research. 2008;191(2):530-9. Download from Science Direct
  • Claxton K. Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics. 2008;9:781-98.
  • Claxton K, Briggs A, Buxton M, Culyer A, McCabe C, Walker S, Sculpher M. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ. 2008;336:251-4. Download from BMJ
  • Claxton K, Culyer A. Not a NICE fallacy: A reply to Dr Quigley. Journal of Medical Ethics. 2008;34:598-601. 
  • Conti S, Claxton K. Dimensions of design space: a decision-theoretic approach to optimal research design. Centre for Health Economics, University of York; CHE Research Paper 38 (PDF , 373kb)‌‎  2008.
  • Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development. Medical Decision Making. 2008;28:21-32. Download from Sage Journals Online
  • Griffin S, Claxton K, Sculpher M. Decision analysis for resource allocation in health care. Journal of Health Services Research and Policy. 2008;13:23-30. Download from RSM Journals
  • McCabe C, Claxton K, O'Hagan A. Why licensing authorities need to consider the net value of new drugs - addressing the tension between licensing and reimbursement. International Journal of Technology Assessment in Health Care. 2008;24:140-5. Download from Cambridge Journals
  • McCabe C, Culyer A, Claxton K. The NICE cost-effectiveness threshold: what it is and what it means. Pharmacoeconomics. 2008;9:733-44.
  • McKenna C, Chalabi Z, Epstein D, Claxton K. Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions. Centre for Health Economics, University of York; CHE Research Paper 44 (PDF , 368kb)‌‎ 2008.
  • Mason A, Walker S, Claxton K, Cookson R, Fenwick E, Sculpher M. The GMS quality and outcomes framework: are the quality and outcomes framework (QOF) indicators a cost-effective use of NHS resources? In: Quality and Outcomes Framework. Joint executive summary: Reports to the Department of Health from the University of East Anglia and the University of York. The GMS quality and outcomes framework (PDF , 238kb)‌‎  
  • Phillips Z, Claxton K, Palmer S. The half-life of truth? what is the appropriate time horizons for research decisions? Medical Decision Making. 2008;28:287-99. Download form Sage Journals Online

2007

  • Bravo Vergal Y, Hawkins N, Claxton K, Asseburg C, Palmer S, Woolacoot N, Bruce IN, Sculpher MJ. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology. 2007;46:1729-35. Download from Oxford Journals
  • Claxton K. OFT,VBP:QED? Health Economics. 2007;16:545-58. Download from Wiley Inter Science
  • Claxton K. The irrelevance of inference: a decision making approach to the stochastic evaluation of health care technologies. Reprinted in: Culyer A, editor. Health Economics: critical perspectives on the world economy. London: Routledge; 2007(0-415-35235-5).
  • Claxton K, Culyer A. Rights, responsibilities and NICE: a rejoinder to Harris. Journal of Medical Ethics. 2007;33:462-4. 
  • Claxton K, Sculpher M, Culyer A. Mark versus Luke? Appropriate methods for the evaluation of public health interventions. Centre for Health Economics, University of York; CHE Research Paper 31 (PDF , 204kb)‌‎ , 2007.
  • Colbourn T, Asseburg C, Bojke L, Phillips Z, Claxton K, Ades A, et al. Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses  Health Technology Assessment. 2007;11(29):1-208. 
  • Colbourn T, Asseburg C, Bojke L, Philips Z, Welton N, Claxton K, et al. Preventive strategies for group B streptococcal and other bacterial infections in early infancy: Cost effectiveness and value of information analyses. British Medical Journal. 2007;Sept 29;335(7621):655.
  • Culyer A, McCabe C, Briggs A, Claxton K, Buxton M, Akehurst R, Sculpher M, Brazier J. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. Journal of Health Services Research and Policy. 2007;12:56-8. 
  • Epstein D, Chalabi Z, Claxton K, Sculpher M. Efficiency, equity and budgetary policies: informing decisions using mathematical programming. Medical Decision Making. 2007;27:128-37. Download from Sage Journals Online
  • Fenwick E, Claxton K, Sculpher MJ. Representing uncertainty: the role of cost-effectiveness acceptability curves. Reprinted in: Culyer A, editor. Health Economics: critical perspectives on the world economy. London: Routledge; 2007 (0415-35235-5).
  • Griffin S, Claxton K, Hawkins N, Sculpher M. Decision models need to be fit for purpose for decision making: response to Caro et al. Value in Health. 2007;10(4):319. Download from Wiley Inter Science
  • McCabe C, Claxton K, Tsuchiya A, Raftery J. Assessing the economics challenges posed by orphan drugs: a comment on Drummond et al. International Journal of Technology Assessment in Health Care. 2007;23:397-401.
  • Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytical cost-effectiveness models: a suggested framework and example of application. Reprinted in: Culyer A, editor. Health Economics: critical perspectives on the world economy. London: Routledge; 2007 (0415-35235-5).

2006

  • Ades A, Claxton K, Sculpher M. Evidence synthesis, parameter correlation and probablistic sensitivity analysis. Health Economics. 2006;15:373-82. Download from Wiley Inter Science
  • Bojke L, Claxton K, Palmer S, Sculpher M. Defining and characterising structural uncertainty in decision analytic models. Centre for Health Economics, University of York; CHE Research Paper 9 (PDF , 229kb)‌‎ , 2006.
  • Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press 2006. Download from Oxford University Press
  • Claxton K, Culyer AJ. Wickedness or folly? The ethics of NICE’s decisions. Journal of Medical Ethics 2006;32: 373-377. 
  • Claxton K, Culyer AJ, Sculpher M, McCabe C, Briggs A, Akehurst R, Brazier J, Buxton M. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion (Editorial). Health Economics 2006;15:1-4. 
  • Claxton K, Sculpher M. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics. 2006;24:1055-68.
  • Claxton K, Sculpher M, Fenwick E. Decision making with uncertainty. In: Jones AM, editor. Companion to health economics: Edward Elgar; 2006.
  • Fenwick E, Palmer S, Claxton K, Sculpher M, Abrams K, Sutton A. An iterative Bayesian approach to health technology assessment: application to a policy of preoperative optimisation for patients undergoing major elective surgery. Medical Decision Making. 2006;26:480-96. Download from Sage Journals Online
  • Griffin S, Claxton K, Hawkins N, Sculpher MJ (2006). Probabilistic analysis and computationally expensive models: necessary and required? Value in Health 2006:9;244-252. Download from Wiley Inter Science
  • Iglesias C, Claxton K. Comprehensive decision analytic modelling and Baysesian value of information analysis: the case of pentoxifylline in the treatment of chronic venous leg ulcers Pharmacoeconomics. 2006;24(5):465-78.
  • McCabe C, Claxton K, Tsuchiya A. Raftery J. Orphan drugs revisited. Quarterly Journal of Medicine. 2006; 99:341-345.Download from Oxford Journals
  • Nelson E, O'Meara S, Craig D, Iglesias C, Golder S, Dalton J, Claxton K. A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers. Health Technology Assessment. 2006;10(12):1-238. 
  • Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality of assessment. Pharmacoeconomics. 2006;24:355-71.
  • Philips Z, Claxton KP, Palmer S, Bojke L, Sculpher MJ. Priority setting for research in health care: an application of value of information analysis to glycoprotein IIb/IIIa antagonists in non-ST elevation acute coronary syndrome. International Journal of Technology Assessment in Health Care 2006;22:379-387.
  • Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making. Health Economics, 2006;15:677-687. Download from Wiley Inter Science
  • Woolacott N, Bravo Vergel Y, Hawkins N, Khadjesari Z, Kaith A, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Chalmers R, Bruce I, Sculpher M, Riemsma R Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technology Assessment 2006; 10(31):1-258 

2005

  • Brazier J, Akehurst R, Brennan A, Dolan P, Claxton K, McCabe C, et al. Should patients have a greater role in valuing health states? Applied Health Economics and Health Policy 2005;4:201-8. 
  • Claxton K, Cohen JT, Neumann PJ. When is evidence sufficient? A framework for making use of all available information in medical decision making and for deciding whether more is needed. Health Affairs 2005;24. Download from Health Affairs
  • Claxton K, Eggington S, Ginnelly L, Griffin S, McCabe C, Philips Z, et al. A pilot study of value of information analysis to support research recommendations for the National Institute for Health and Clinical Excellence. Centre for Health Economics, University of York; CHE Research Paper 4 (PDF , 1,149kb)‌‎ , 2005.
  • Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, Brazier J, O'Hagan T. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics 2005;14(4):339-347. Download from Wiley Inter Science
  • Epstein D, Chalabi Z, Claxton K, Sculpher M. Mathematical programming for the optimal allocation of health care resources. Poster presentation at IHEA conference, Barcelona July 2005. Download here
  • Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information. combined and uneven development. Centre for Health Economics, University of York; CHE Research Paper 5 (PDF , 251kb)‌‎ , 2005.
  • Ginnelly L, Claxton K, Sculpher MJ, Golder S. Using value of information analysis to inform publicly funded research priorities. Applied Health Economics and Health Policy 2005;4:37-46.
  • McCabe C, Claxton K, Tsuchiya A. Special status for orphan drugs in health care decision making processes: a wise move? . British Medical Journal. 2005;331:1016-9. Download from BMJ
  • O'Hagan A, McCabe C, Akehurst R, Brennan A, Briggs A, Claxton K, Fenwick E, Fryback D, Sculpher M, Spiegelhalter D, Willan A. Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics 2005;23:529-36.
  • Organised session at the International Health Economics Association meeting, Barcelona, July 2005: 'The role of trial-based economic evaluation in health care decision making. Download here
  • Schultz G, Mozingo D, Romanelli M, Claxton K. Wound healing and TIME; new concepts and scientific applications. Wound Repair and Regeneration. 2005;4((Suppl)):S1-S11.
  • Sculpher M, Claxton K. The use of economic evaluation for decision making: methodological opportunities and challenges. Presentation as part of an organised session 'Using cost-effectiveness studies to inform technology coverage decision-making: some evidence, some opinions and some challenges' at the International Health Economics Association meeting, Barcelona, July 2005. Download here
  • Sculpher M, Claxton K. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty - when is there sufficient eveidence Value in Health. 2005;8:433-46. Download from Wiley Inter Science
  • Sculpher M, Claxton K, Akehurst R. It's just evaluation for decision-making: recent developments in, and challenges for, cost-effectiveness research. In: Smith PC, Ginnelly L, Sculpher M, editors. Health policy and economics: opportunities and challenges: Maidenhead: Open University Press; 2005. p. 8-41.

2004

  • Ades AE, Lu G, Claxton K. Expected value of sample information calculations in medical decision modelling. Medical Decision Making 2004;24:207-27. Download from Sage Journals Online
  • Claxton K, Fenwick E, Palmer S, Sculpher M, Abrams K, Sutton A. Building a reference case for Bayesian applications to health economics and outcome research. CHE Technical Paper 35 (PDF , 5,325kb)‌‎ : York: Centre for Health Economics; 2004. 
  • Claxton K, Ginnelly L, Sculpher MJ, Philips Z, Palmer S. A pilot study on the use of decision theory and value of information analysis as part of the National Health Service Health Technology Assessment Programme. Health Technology Assessment 2004;8(31):1-118. 
  • Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, Woolacoot N, Glanville J. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technology Assessment 2004;8(36):1-172. 

2003

  • Chilcott J, McCabe C, Tappenden P, O'Hagan A, Cooper NJ, Abrams K, Claxton K. Modelling the cost-effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. British Medical Journal. 2003;326:522-6. Download from BMJ
  • Dowie J, Claxton K, Sculpher M, Drummond M. NICE (and the NHS) - quo vadis. In: Oliver A, editor. Health care priority setting: implications for health inequalities. Proceedings from a meeting of the Health Equity Network: London: The Nuffield Trust; 2003. p. 9-15.
  • Mohr P, Cheng M, Claxton K, Conley R, Feldman A, Hargreaves W, et al. Capturing the heterogeneity of schizophrenia in economic models. Schizophrenia Research. 2003;71(1):83-95.

2002

  • Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence. Lancet 2002;360:711-715. Download from Pub Med
  • Fenwick E, Wilson J, Sculpher M, Claxton K. Pre-operative optimisation employing dopexamine or adrenaline for patients undergoing major elective surgery: a cost-effectiveness analysis. Intensive Care Medicine 2002;28:599-608. Download from Pub Med

2001

  • Claxton K, Neuman PJ, Araki SS, Weinstein MC. The value of information: an application to a policy model of Alzheimer's disease. International Journal of Technology Assessment in Health Care 2001;17:38-55.
  • Claxton K, Thompson K. A dynamic programming approach to efficient clinical trial design. Journal of Health Economics 2001;20:797-822. Download from Science Direct
  • Fenwick E, Claxton K, Sculpher MJ. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Economics. 2001;10:779-89. Download from Wiley Inter Science
  • Luce B, Ya-Chen TS, Claxton K. A Bayesian approach to decision making in health care. International Journal of Technology Assessment in Health Care. 2001;17:1-8.

2000

  • Claxton K, Walker S, Lacey L. Selecting treatments: a decision theoretic approach. Journal of the Royal Statistical Society 2000;163(2):211-225.
  • Neuman P, Claxton K, Weinstein MC. FDA regulation of health economic information: issues and options for section 114 of FDA modernization act. Health Affairs. 2000;Fall(129-137).
  • Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytical cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics. 2000 May;17(5):461-77.

1999

  • Claxton K. The irrelevance of inference: a decision making approach to the stochastic evaluation of health care technologies. Journal of Health Economics. 1999;18(3):341-64. Download from Science Direct
  • Claxton K. Bayesian approaches to the value of information: implications for the regulation of new care technologies. Health Economics. 1999;8(3):269-74. Download from Wiley Inter Science
  • Luce B, Claxton K. Redefining the analytical approach to pharmacoeconomics. Health Economics 1999;8(3):187-9. Download from Wiley Inter Science 1998
  • Mohr P, Neumann P, Claxton K. Economic models of the treatment of schizophrenia. American Journal of Managed Care. 1998;4(8):1200-1.

1996

  • Claxton K, Posnett J. An economic approach to clinical trial design and research priority setting. Health Economics. 1996;5(6):513-24. Download from Wiley Inter Science

Conference Papers

Teaching

Other teaching

Centre for Health Economics



Staff Photo for Karl Claxton

Contact details

Prof. Karl Claxton
Professor of Economics
Centre for Health Economics